Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818371 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2PKMKDM4EHSD17B1MAPK1 | |
| SCHEMBL14698246 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2PKMKDM4EMAPK1ALDH1A1 | |
| SCHEMBL29818557 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2PKMKDM4EMAPK1ALDH1A1 | |
| SCHEMBL17646774 | 0.78 | PKM (0.35) | SMN1; SMN2PKMKDM4EMAPK1ALDH1A1 | |
| SCHEMBL22296106 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2PKMKDM4EMAPK1ALDH1A1 | |
| SCHEMBL17647565 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2PKMKDM4EMAPK1ALDH1A1 | |
| SCHEMBL16019317 | 0.67 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4EMAPK1ALDH1A1GAA | |
| SCHEMBL4107462 | 0.67 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPK1ALDH1A1GAA | |
| SCHEMBL29741196 | 0.67 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4EMAPK1ALDH1A1GAA | |
| SCHEMBL2902560 | 0.66 | KDM4E (0.45) | SMN1; SMN2KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4284804-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | Schrödinger, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022164789-A9 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022164789-A9 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022164789-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS | SCHRÖDINGER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-9351969-B2 | Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (CETP) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-05-31 | — | — | US | disclosed |
| US-9351969-B2 | Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (CETP) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-05-31 | — | — | US | disclosed |
| US-9351969-B2 | Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (CETP) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20160045488-A1 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| US-20160045488-A1 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| US-20160045488-A1 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-02-18 | — | — | US | disclosed |
| US-9199967-B2 | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-01 | — | — | US | disclosed |
| US-9199967-B2 | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-01 | — | — | US | disclosed |
| US-9199967-B2 | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-01 | — | — | US | disclosed |
| US-20140256724-A1 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTRYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-09-11 | — | — | US | disclosed |
| US-20140256724-A1 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTRYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-09-11 | — | — | US | disclosed |
| US-20140256724-A1 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTRYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-09-11 | — | — | US | disclosed |
| EP-2744803-A2 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTRYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013024358-A2 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTRYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024358-A2 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTRYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | SMN1; SMN2 3734/4885PKM 2176/4885KDM4E 3981/4885 |
| US-20160045488-A1 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | CETP, MTTP, PCTP | SMN1; SMN2 4877/4885PKM 1351/4885KDM4E 3080/4885 |
| US-20140256724-A1 | SUBSTITUTED HETEROCYCLIC AMINE COMPOUNDS AS CHOLESTRYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS | CETP, MTTP, PCTP | SMN1; SMN2 4859/4885PKM 1567/4885KDM4E 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.